Gabapentin Reduces Cocaine Use Among Addicts From a Community Clinic Sample
J Clin Psychiatry 2004;65(1):84-86
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: Individuals with chronic
psychiatric conditions display a high rate of cocaine use.
Gabapentin was hypothesized to reduce cocaine use by restoring
inhibitory GABAergic feedback on ascending dopaminergic
projections to nucleus accumbens neurons.
Method: Nine participants with DSM-IV
cocaine dependence were selected from patients attending a large
community psychiatric clinic. During a 24-week open-label trial
of gabapentin (800-2400 mg/day), qualitative urine drug screens
were collected from the participants up
to 3 times per week. Data were collected from
September 1999 to May 2001.
Results: With gabapentin, the mean ± SD number
of cocaine-positive urine screens decreased from 53.11 ± 13.23
to 35.22 ± 14.84 (t = 3.58, N = 9, p < .01). The number of
weeks of abstinence from cocaine increased from 2.1 ± 1.5 to 8.0
± 5.5 (t = 3.21, N = 9, p < .01).
Conclusion: Gabapentin appeared to be a safe and
efficacious medication to reduce cocaine usage in a community
sample of psychiatric patients.